{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:00:26Z","timestamp":1761894026332,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":6464,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1038\/modpathol.3800333","type":"journal-article","created":{"date-parts":[[2004,11,5]],"date-time":"2004-11-05T06:58:50Z","timestamp":1099637930000},"page":"651-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Samuel A","family":"Yousem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.3800333_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","article-title":"Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden","volume":"61","author":"Geborek","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/modpathol.3800333_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","article-title":"Rational use of new and existing disease-modifying agents in rheumatoid arthritis","volume":"134","author":"Kremer","year":"2001","journal-title":"Ann Int Med"},{"key":"10.1038\/modpathol.3800333_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.3800333_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc Fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.3800333_bib5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Int Med"},{"key":"10.1038\/modpathol.3800333_bib6","first-page":"1981","article-title":"Long-term use of etanercept in patients with dmard-refractory rheumatoid arthritis","volume":"S401","author":"Moreland","year":"2000","journal-title":"RA Genetics, ACR Abstract Concurrent Session"},{"key":"10.1038\/modpathol.3800333_bib7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0149-2918(03)80313-2","article-title":"An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis","volume":"25","author":"Weinberg","year":"2003","journal-title":"Clin Ther"},{"key":"10.1038\/modpathol.3800333_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1038\/modpathol.3800333_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.3800333_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","article-title":"Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept","volume":"25","author":"Fleischmann","year":"2002","journal-title":"Drug Saf"},{"issue":"Suppl 2","key":"10.1038\/modpathol.3800333_bib11","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.62.suppl_2.ii30","article-title":"Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis","volume":"62","author":"Flendrie","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1038\/modpathol.3800333_bib12","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.62.suppl_2.ii30","article-title":"Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis","volume":"62","author":"Flendrie","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/modpathol.3800333_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/ard.61.9.850","article-title":"Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis","volume":"61","author":"Soliotis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/modpathol.3800333_bib14","first-page":"1238","article-title":"Long term safety and efficacy on etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1038\/modpathol.3800333_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.11154","article-title":"Pulmonary rheumatoid nodules in an etanercept-treated patient","volume":"48","author":"Hubscher","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1038\/modpathol.3800333_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.10096","article-title":"Development of rheumatoid nodules during anti-tumor necrosis factor \u03b1 therapy with etanercept","volume":"46","author":"Kekow","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1038\/modpathol.3800333_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/art.10535","article-title":"Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis","volume":"47","author":"Cunnane","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1038\/modpathol.3800333_bib18","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1378\/chest.122.5.1858","article-title":"Lung injury linked to etanercept therapy","volume":"122","author":"Peno-Green","year":"2002","journal-title":"CHEST"},{"key":"10.1038\/modpathol.3800333_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00000478-200003000-00006","article-title":"Epstein\u2013Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?","volume":"24","author":"Nelson","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.3800333_bib20","first-page":"770","article-title":"Lung biopsy in rheumatoid arthritis","volume":"131","author":"Yousem","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1038\/modpathol.3800333_bib21","first-page":"10","article-title":"Histopathological approach to patterns of interstitial pneumonia in patients with connective tissue disorders","volume":"19","author":"Nicholson","year":"2002","journal-title":"Sarcoidosis Vase Diffuse Lung Dis"},{"key":"10.1038\/modpathol.3800333_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.95.08030472","article-title":"Association of the histologically proven rheumatoid arthritis with pulmonary sarcoidosis","volume":"8","author":"Menard","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1038\/modpathol.3800333_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/BF02208160","article-title":"Mutilating rheumatoid arthritis associated with sarcoidosis: a case report","volume":"14","author":"Takashita","year":"1995","journal-title":"Clin Rheumatol"},{"key":"10.1038\/modpathol.3800333_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1365-2133.2002.4653_4.x","article-title":"Dermatological complications of etanercept therapy for rheumatoid arthritis","volume":"146","author":"Misery","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1038\/modpathol.3800333_bib25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/14656566.5.5.1175","article-title":"Etanercept: a clinical review of current and emerging indications","volume":"5","author":"Nanda","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1038\/modpathol.3800333_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11926-003-0005-9","article-title":"Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis","volume":"5","author":"Mikuls","year":"2003","journal-title":"Curr Rheum Rep"},{"key":"10.1038\/modpathol.3800333_bib27","first-page":"726","article-title":"B cell activation in rheumatoid arthritis patients under infliximab treatment","volume":"21","author":"De Miguel","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1038\/modpathol.3800333_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"CHEST"},{"key":"10.1038\/modpathol.3800333_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0046-8177(85)80155-6","article-title":"Follicular bronchitis\/bronchiolitis","volume":"16","author":"Yousem","year":"1985","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.3800333_bib30","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1378\/chest.124.3.1174","article-title":"Etanercept or mycobacterium lung injury?","volume":"124","author":"Fennelly","year":"2003","journal-title":"CHEST"},{"key":"10.1038\/modpathol.3800333_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1034\/j.1399-3003.2000.15b25.x","article-title":"Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients","volume":"15","author":"Imokawa","year":"2000","journal-title":"Eur Respir J"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/3800333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/3800333","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222046385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222046385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/3800333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:21:25Z","timestamp":1760232085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222046385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0893395222046385"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.3800333","relation":{},"ISSN":["0893-3952"],"issn-type":[{"type":"print","value":"0893-3952"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.3800333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}